BioSpace News Archive

Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced receipt of clearance from the Brazilian regulatory agency (ANVISA) to proceed with a PHASE 2A RANDOMIZED, PLACEBO-CONTROLLED STUDY OF INTRAVENOUS ALLOGENEIC ADIPOSE-DERIVED MESENCHYMAL STROMAL CELLS TO TREAT POST COVID-19 “LONG HAUL” PULMONARY COMPROMISE (NCT04992247).

Clarius Mobile Health introduced its third-generation product line of high-performance handheld wireless ultrasound scanners for veterinarians.

Neuropathix, Inc., a socially responsible pain management life sciences company, announces that the Company has been issued Indian Patent IN201617027528 specific to its global patent known as WO2015/106108A2 titled, “Novel Functionalized 1,3-Benzene Diols and their Method of Use for the Treatment of Hepatic Encephalopathy”.

UCB, a global biopharmaceutical company, today announced positive top-line interim analysis results showing that the Phase 3 BE MOBILE 1 study met the primary and all ranked secondary endpoints.

Olympus today announced abstract findings of independent clinical studies that show the treatment of kidney stones with the SOLTIVE™ Premium SuperPulsed Laser System (SOLTIVE Laser System) may offer the potential for shorter procedure times, better patient outcomes and lower procedures costs than those performed with Holmium: YAG.

Aromyx, a leading company in applying biotechnology and data science to capture unique sensory data, announced that retail and Consumer Packaged Goods consumer insights expert, Elise Kern, has joined the company as SVP of Data and Insights.

Lexaria Bioscience Corp., a global innovator in drug delivery platforms, comments on an independent January 10 study, available here, that discovered that “Cannabinoids Block Cellular Entry of SARS-CoV-2 and the Emerging Variants”.

SoftSmile, a leading medical technology company based in NY, and developer of advanced orthodontic software solutions, announced its software device was cleared by the U.S. Food and Drug Administration (FDA) pursuant to a 510(k) pre-market notification.

Following on the heels of the Company’s initial release of encouraging preliminary results in November 2021, the trial data submitted last week further demonstrate the high levels of efficacy and safety previously observed for MesenCure’s treatment of severe COVID-19 patients.

The global laboratory mixer market is projected to be valued at USD 2.25 billion by end of 2027 from USD 1.6 billion in 2020, expanding at a CAGR of 3.7% during the forecast period.